The Impact of Biosimilar Competition. Five Observations by IMS Health

The report presents a set of Key Performance Indicators (KPIs) for European countries. In this document IMS Health suggests five key observations based on the data

IMS Health has produced the report The Impact of Biosimilar Competition (based on 2014 figures) for the European Commission. The report has been published in December 2015. Input to the report was given by the European Generic medicines Association, the European Federation of Pharmaceutical Industries and Associations and and EuropaBio, the European Association of Bio-Industries. The report presents a set of Key Performance Indicators (KPIs) for European countries. In this document IMS Health suggests five key observations based on the data.

Documenti collegati: